HSC activation results in redistribution of LDs and is accompanied by a decrease in size. by Nicole Testerink (169448)

The activity of platelet P2Y1, but not of P2X1 or P2Y12 receptor, continually decreases in citrated WB. by Juergen Koessler (847843)

Comparison of human measures of motor learning across the Start phase (5 first games) and the Middle phase (5 middle games) of <i>Auto Orbit</i>. by Pierre Giovanni Gianferrara (11553077)

Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

“…Outcomes from the model included life expectancy, 10-year medical resource use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/<i>μ</i>L, SD 198/<i>μ</i>L) and transmitted cases. …”

LAP whole blood displays Increased capacity for 5-HETE and LTB₄ levels, and decreased for 12-HETE, 14-HDHA, 15-HETE and LXA₄. by Gabrielle Fredman (272178)

Vasodilator effect of BPP-BrachyNH₂ and captopril (10⁻⁹–3 × 10⁻⁵ M) on rat thoracic aorta. by Daniel Dias Rufino Arcanjo (536744)

Transgenic <i>Eμ-V_H-OBF1</i> mice are immunodeficient due to decreased numbers of follicular B cells. by Alain Bordon (57422)

mGluR5 binding potential (BP_ND) decreased in epilepsy models according to time periods after status epilepticus. by Hongyoon Choi (541919)

“…<p>(A–C) BP_ND decreased globally in acute period after status epilepticus. …”

CDK5 knockdown increases TP53 and p27^Kip1 protein half-lives, increases nuclear localization of the two proteins, decreases p27^Kip1 p-T187 phosphorylation and induces p21^Cip1 in a TP53-dependent manner. by Shu Zhang (22238)

“…<p>(<b>A</b>) Transfection with CDK5 siRNA increased the half-life of p53 and p27^Kip1 protein. …”

Activation of vMC-dDG pathway decreases the competitive advantage of fear engram cells in the dDG neuronal network and attenuates fear generalization. by Kun Cui (2070772)

Effect of freeze-thaw cycling on grain size of biochar - Fig 5 by Zuolin Liu (633898)

Distribution and characteristics of CD5⁺ and CD5^- B cells in normal mice. by Yoshiyuki Mishima (842248)

Quantification of <i>ATP5B</i> mRNA and β-F1-ATPase protein expression shows decreased protein translation in obesity. by Lee Tran (2106961)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”

Reformation of oxygen gradient in a disturbed sediment. by Xuegang Mao (599968)

Subjects:

Removal of the A-B linker did not decrease PIP₂ affinity. <i>A.-</i> by Paloma Aivar (124885)

Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines. by Octavian Bucur (470431)

“…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”

Decreased neutrophil levels in HIF^C mice correlates to decreased production of CXCL1 and not migration defects. by Kelly M. Shepardson (404375)

(R+S) and (R)-albuterol decrease NF-κB activity by Marcela A Ferrada (41716)

“…After transfection, (R)-albuterol (R), (S)-albuterol (S), or racemic albuterol (R+ S) were added to cells pre-activated with (ConA, 5 μg/ml) and (PMA, 100 ng/ml) (CP) and then treated with (R)-, (S)-, or (R+S)-albuterol (Fig. 6). …”